CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment

Giovanni Frisullo, Raffaele Iorio, Domenico Plantone, Alessandro Marti, Viviana Nociti, Agata Katia Patanella, Anna Paola Batocchi

Research output: Contribution to journalArticle

Abstract

Circulating T cells and monocytes expressing T-bet, pSTAT1 and pSTAT3 increase in relapsing-remitting multiple sclerosis (RRMS) during relapse. Natalizumab (NZB) is an effective drug in RRMS, but exacerbation of the disease after its discontinuation has been described in some patients. The aim of this research was to study the effect of NZB treatment on circulating lymphomonocyte subpopulations expressing T-bet, pSTAT1, pSTAT3 and CD4+CD25 +Foxp3+ regulatory T cells. Flow cytometry was used to evaluate the percentages of circulating CD4+ and CD8+ T cells, CD14+ monocytes and B cells expressing T-bet, pSTAT1, and pSTAT3, and CD4+CD25+Foxp3+ regulatory T cells from RRMS patients before and after 6-12 NZB infusions. In NZB-treated RRMS patients, the percentages of CD4+pSTAT1+ and CD8 +pSTAT1+ T cells, CD14+pSTAT1+ monocytes, CD4+T-bet+, CD8+T-bet+ and CD4+pSTAT3+ T cells and CD14+pSTAT3 + monocytes increased after 12 drug infusions and were similar to those observed in untreated relapsing RRMS patients. Otherwise in vitro NZB exposure of peripheral blood mononuclear cells from untreated RRMS patients and controls had no effect. It was concluded that NZB treatment determines an accumulation of CD4+pSTAT1+, CD8+pSTAT1 +, CD4+T-bet+, CD8+T-bet+ and CD4+STAT3+ T cells in peripheral blood that may account for the exacerbation of the disease observed in some patients after the discontinuation of the drug.

Original languageEnglish
Pages (from-to)556-566
Number of pages11
JournalMultiple Sclerosis Journal
Volume17
Issue number5
DOIs
Publication statusPublished - 2011

Fingerprint

Relapsing-Remitting Multiple Sclerosis
T-Lymphocytes
Monocytes
Regulatory T-Lymphocytes
Disease Progression
Therapeutics
Pharmaceutical Preparations
Natalizumab
Blood Cells
Flow Cytometry
B-Lymphocytes
Recurrence
Research

Keywords

  • B cells
  • Monocytes
  • Multiple sclerosis
  • Natalizumab
  • PSTAT1
  • PSTAT3
  • T cells
  • T-bet

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment. / Frisullo, Giovanni; Iorio, Raffaele; Plantone, Domenico; Marti, Alessandro; Nociti, Viviana; Patanella, Agata Katia; Batocchi, Anna Paola.

In: Multiple Sclerosis Journal, Vol. 17, No. 5, 2011, p. 556-566.

Research output: Contribution to journalArticle

Frisullo, Giovanni ; Iorio, Raffaele ; Plantone, Domenico ; Marti, Alessandro ; Nociti, Viviana ; Patanella, Agata Katia ; Batocchi, Anna Paola. / CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment. In: Multiple Sclerosis Journal. 2011 ; Vol. 17, No. 5. pp. 556-566.
@article{ed0c48ee388f447bbea77c1b4bd4a377,
title = "CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment",
abstract = "Circulating T cells and monocytes expressing T-bet, pSTAT1 and pSTAT3 increase in relapsing-remitting multiple sclerosis (RRMS) during relapse. Natalizumab (NZB) is an effective drug in RRMS, but exacerbation of the disease after its discontinuation has been described in some patients. The aim of this research was to study the effect of NZB treatment on circulating lymphomonocyte subpopulations expressing T-bet, pSTAT1, pSTAT3 and CD4+CD25 +Foxp3+ regulatory T cells. Flow cytometry was used to evaluate the percentages of circulating CD4+ and CD8+ T cells, CD14+ monocytes and B cells expressing T-bet, pSTAT1, and pSTAT3, and CD4+CD25+Foxp3+ regulatory T cells from RRMS patients before and after 6-12 NZB infusions. In NZB-treated RRMS patients, the percentages of CD4+pSTAT1+ and CD8 +pSTAT1+ T cells, CD14+pSTAT1+ monocytes, CD4+T-bet+, CD8+T-bet+ and CD4+pSTAT3+ T cells and CD14+pSTAT3 + monocytes increased after 12 drug infusions and were similar to those observed in untreated relapsing RRMS patients. Otherwise in vitro NZB exposure of peripheral blood mononuclear cells from untreated RRMS patients and controls had no effect. It was concluded that NZB treatment determines an accumulation of CD4+pSTAT1+, CD8+pSTAT1 +, CD4+T-bet+, CD8+T-bet+ and CD4+STAT3+ T cells in peripheral blood that may account for the exacerbation of the disease observed in some patients after the discontinuation of the drug.",
keywords = "B cells, Monocytes, Multiple sclerosis, Natalizumab, PSTAT1, PSTAT3, T cells, T-bet",
author = "Giovanni Frisullo and Raffaele Iorio and Domenico Plantone and Alessandro Marti and Viviana Nociti and Patanella, {Agata Katia} and Batocchi, {Anna Paola}",
year = "2011",
doi = "10.1177/1352458510392263",
language = "English",
volume = "17",
pages = "556--566",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment

AU - Frisullo, Giovanni

AU - Iorio, Raffaele

AU - Plantone, Domenico

AU - Marti, Alessandro

AU - Nociti, Viviana

AU - Patanella, Agata Katia

AU - Batocchi, Anna Paola

PY - 2011

Y1 - 2011

N2 - Circulating T cells and monocytes expressing T-bet, pSTAT1 and pSTAT3 increase in relapsing-remitting multiple sclerosis (RRMS) during relapse. Natalizumab (NZB) is an effective drug in RRMS, but exacerbation of the disease after its discontinuation has been described in some patients. The aim of this research was to study the effect of NZB treatment on circulating lymphomonocyte subpopulations expressing T-bet, pSTAT1, pSTAT3 and CD4+CD25 +Foxp3+ regulatory T cells. Flow cytometry was used to evaluate the percentages of circulating CD4+ and CD8+ T cells, CD14+ monocytes and B cells expressing T-bet, pSTAT1, and pSTAT3, and CD4+CD25+Foxp3+ regulatory T cells from RRMS patients before and after 6-12 NZB infusions. In NZB-treated RRMS patients, the percentages of CD4+pSTAT1+ and CD8 +pSTAT1+ T cells, CD14+pSTAT1+ monocytes, CD4+T-bet+, CD8+T-bet+ and CD4+pSTAT3+ T cells and CD14+pSTAT3 + monocytes increased after 12 drug infusions and were similar to those observed in untreated relapsing RRMS patients. Otherwise in vitro NZB exposure of peripheral blood mononuclear cells from untreated RRMS patients and controls had no effect. It was concluded that NZB treatment determines an accumulation of CD4+pSTAT1+, CD8+pSTAT1 +, CD4+T-bet+, CD8+T-bet+ and CD4+STAT3+ T cells in peripheral blood that may account for the exacerbation of the disease observed in some patients after the discontinuation of the drug.

AB - Circulating T cells and monocytes expressing T-bet, pSTAT1 and pSTAT3 increase in relapsing-remitting multiple sclerosis (RRMS) during relapse. Natalizumab (NZB) is an effective drug in RRMS, but exacerbation of the disease after its discontinuation has been described in some patients. The aim of this research was to study the effect of NZB treatment on circulating lymphomonocyte subpopulations expressing T-bet, pSTAT1, pSTAT3 and CD4+CD25 +Foxp3+ regulatory T cells. Flow cytometry was used to evaluate the percentages of circulating CD4+ and CD8+ T cells, CD14+ monocytes and B cells expressing T-bet, pSTAT1, and pSTAT3, and CD4+CD25+Foxp3+ regulatory T cells from RRMS patients before and after 6-12 NZB infusions. In NZB-treated RRMS patients, the percentages of CD4+pSTAT1+ and CD8 +pSTAT1+ T cells, CD14+pSTAT1+ monocytes, CD4+T-bet+, CD8+T-bet+ and CD4+pSTAT3+ T cells and CD14+pSTAT3 + monocytes increased after 12 drug infusions and were similar to those observed in untreated relapsing RRMS patients. Otherwise in vitro NZB exposure of peripheral blood mononuclear cells from untreated RRMS patients and controls had no effect. It was concluded that NZB treatment determines an accumulation of CD4+pSTAT1+, CD8+pSTAT1 +, CD4+T-bet+, CD8+T-bet+ and CD4+STAT3+ T cells in peripheral blood that may account for the exacerbation of the disease observed in some patients after the discontinuation of the drug.

KW - B cells

KW - Monocytes

KW - Multiple sclerosis

KW - Natalizumab

KW - PSTAT1

KW - PSTAT3

KW - T cells

KW - T-bet

UR - http://www.scopus.com/inward/record.url?scp=80053409357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053409357&partnerID=8YFLogxK

U2 - 10.1177/1352458510392263

DO - 10.1177/1352458510392263

M3 - Article

C2 - 21177324

AN - SCOPUS:80053409357

VL - 17

SP - 556

EP - 566

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 5

ER -